Oncologia Medica 1, Ospedale Busonera, via Gattamelata 64, 35128 Padova, Italy. Mobile: +39 3479775504,
Anticancer Res. 2013 Dec;33(12):5531-4.
Radiation-refractory and progressive Kaposi's sarcoma remains a challenge for the oncologist. Systemic chemotherapy has improved, but results are poor. Gemcitabine is largely employed in oncology for its high therapeutic rates. We report four cases of patients with radiation-refractory and progressive classic Kaposi's sarcoma, two of whom were pre-treated with chemotherapy and then underwent treatment with gemcitabine. All patients had an objective response with long progression-free survival. Gemcitabine seems to be very effective and safe in the treatment of classic Kaposi's sarcoma.
对于肿瘤学家来说，辐射难治性和进行性卡波西肉瘤仍然是一个挑战。全身化疗有所改善，但结果不佳。吉西他滨因其高治疗率而在肿瘤学中得到广泛应用。我们报告了 4 例患有辐射难治性和进行性经典卡波西肉瘤的患者，其中 2 例患者在接受化疗预处理后接受了吉西他滨治疗。所有患者均有客观反应，且无进展生存期较长。吉西他滨治疗经典卡波西肉瘤似乎非常有效且安全。
